Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15520747 | 0.80 | GRM5 (0.56) | GRM5CYP11B2MGLLIRAK4CYP11B1 | |
| SCHEMBL46326 | 0.78 | GRM5 (0.57) | GRM5CYP11B2MGLLIRAK4CYP11B1 | |
| SCHEMBL1053384 | 0.76 | GRM5 (0.56) | GRM5CYP11B2MGLLIRAK4CYP11B1 | |
| SCHEMBL2398608 | 0.76 | GRM5 (0.56) | GRM5CYP11B2MGLLIRAK4CYP11B1 | |
| SCHEMBL18307164 | 0.76 | GRM5 (0.56) | GRM5CYP11B2MGLLIRAK4CYP11B1 | |
| SCHEMBL23111145 | 0.76 | GRM5 (0.62) | GRM5CYP11B2MGLLIRAK4CYP11B1 | |
| Hydrochloric Acid SCHEMBL23168041 | 0.75 | GRM5 (0.55) | GRM5CYP11B2MGLLIRAK4CYP11B1 | |
| SCHEMBL14242972 | 0.75 | GRM5 (0.57) | GRM5CYP11B2MGLLKDM4EATM | |
| SCHEMBL838774 | 0.75 | GRM5 (0.60) | GRM5CYP11B2MGLL | |
| SCHEMBL21863669 | 0.74 | GRM5 (0.53) | GRM5CYP11B2MGLLIRAK4CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231653-B1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2013-04-03 | — | — | EP | disclosed |
| US-8299065-B2 | Antibacterial condensed thiazoles | BIOTA EUROPE LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2010-12-02 | — | — | US | disclosed |
| EP-2231653-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | Biota Europe Ltd (GB) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074812-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | PROLYSIS LTD (GB) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | NEK6, NEK1, TXK | GRM5 3528/4885CYP11B2 2553/4885MGLL 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.